Clinical Trials on Immunologic Disease in Australia

Total 13443 results

CSL Limited

Completed

Subcutaneous Ig NextGen 16% in PID Patients

Primary Immunodeficiency (PID)

Australia, New Zealand
Kirby Institute
Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme LLC; Roche Pharma AG; Boehringer... and other collaborators

Completed

Can Resistance Enhance Selection of Treatment? (CREST)

HIV Infection

Australia
Tunitas Therapeutics, Inc.
Tunitas Therapeutics Australia Pty Ltd

Terminated

Escalating Single Dose Study of Epsi- Gam in Healthy Normal Subjects

Allergy and Immunology

Australia
Medical University of Vienna
Elisabethinen Hospital

Terminated

Combined Apheresis for ABO-incompatible Transplantation - a Pilot Study

Antibody-mediated Rejection | Decreased Immunologic Activity

Austria
CSL Limited

Completed

Ig NextGen 10% in Patients With Primary Immune Deficiency (PID)

Primary Immune Deficiency (PID)

Australia
Monash University

Recruiting

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension (RATIONALISE)

Hypogammaglobulinemia | Haematological Malignancy

Australia
Medical University of Vienna
Fresenius Medical Care Deutschland GmbH

Completed

ABO Blood Group Antibody Elimination by a Combination of Semiselective Immunoadsorption Therapy and Membrane Filtration

Immunology

Austria
Evopoint Biosciences Inc.

Completed

The the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XNW3009 in Health Subject

Gout

Australia
International Antiviral Therapy Evaluation Center
Boehringer Ingelheim

Completed

2NN & CHARM Long-Term Follow-up Study

HIV Infections

Australia
ADARx Pharmaceuticals, Inc.

Recruiting

Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients

Hereditary Angioedema

Australia
CSL Behring

Recruiting

First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects

Complement Deficiencies

Australia
The Canberra Hospital

Completed

Intravenous Saline Pre-hydration in Patients Undergoing Outpatient Colonoscopy

Colonic Diseases

Australia
Bayside Health

Unknown

The Role of Naive T-Cells in HIV Pathogenesis

HIV Infections

Australia
The Alfred
National Health and Medical Research Council, Australia

Completed

IL-7 Receptor Polymorphisms and Immune Recovery With HAART

HIV Infections

Australia
Avexa

Completed

AVX754 (a New Nucleoside Reverse Transcriptase Inhibitor [NRTI]) to Treat Drug-resistant HIV

HIV Infections

Australia
Avexa

Completed

A Long Term, Safety Study of Apricitabine in HIV-infected Subjects

HIV Infection

Australia
University of Melbourne
Merck Sharp & Dohme LLC; The Alfred

Terminated

Combination Latency Reversal With High Dose Disulfiram Plus Vorinostat in HIV-infected Individuals on ART

HIV Infections

Australia
Bayside Health

Completed

The Effects of a Supervised Exercise Program on Self Efficacy of People Living With HIV/AIDS.

HIV Infections

Australia
CSL Limited

Completed

Safety Study of Subcutaneous Ig NextGen 16% in Patients With Primary Immunodeficiency

Primary Immune Deficiency

Australia, New Zealand
Bayside Health
Merck Sharp & Dohme LLC

Unknown

Safety and Effect on HIV Transcription of Vorinostat in Patients Receiving Suppressive Combination Anti-retroviral Therapy

HIV Positive

Australia
Octapharma

Terminated

Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency Diseases

Immunologic Deficiency Syndromes

Austria
The Alfred
National Health and Medical Research Council, Australia

Completed

Impact of HIV and Its Treatment on Reverse Cholesterol Transport

HIV Infections

Australia
Kirby Institute

Completed

A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine: The STEAL Study

HIV Infections

Australia
Starpharma Pty Ltd
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

SPL7013 Gel - Male Tolerance Study

Human Immunodeficiency Virus (HIV)

Australia
University of Melbourne
Melbourne Health; National Institute of Allergy and Infectious Diseases (NIAID) and other collaborators

Completed

Effect of High Dose Vitamin D Supplementation on HIV Latency (VIVA)

Human Immunodeficiency Virus

Australia
Holdsworth House Medical Practice
Atomo Diagnostics

Completed

Performance and Usability Evaluation of the Atomo HIV Self-Test

HIV Infections

Australia
Kirby Institute
Hoffmann-La Roche

Completed

A 48-Week, Randomised, Study to Describe the Pharmacokinetic Profile and Durability of Atazanavir-Saquinavir-Ritonavir Once Daily and Describe the Pharmacokinetic Profile of Saquinavir-Ritonavir Using Saquinavir 500mg Formulation: the ASK-500 Study (ASK-500)

HIV Infections

Australia
Kirby Institute

Completed

Safety and Efficacy of Reduced Versus Standard Dose Efavirenz (EFV) Plus Two Nucleotides in Antiretroviral-naïve Adults. (ENCORE1)

HIV Infections

Australia
National Institute of Allergy and Infectious Diseases...

Completed

Evaluation of the Safety of and Immune Response to an HIV Vaccine in Healthy Adults

HIV Infections

Australia
Andrew Carr
Merck Sharp & Dohme LLC

Completed

Raltegravir Use as Nonoccupational Postexposure Prophylaxis (NPEP) in Men Who Have Sex With Men (RAL-NPEP)

HIV Infections | HIV Prevention

Australia
Kirby Institute

Completed

Raltegravir and Atazanavir Dosing Strategy Study (SPARTA)

HIV Infection

Australia
Holdsworth House Medical Practice

Completed

RETRIeVE: ReversE TranscRiptase Inhibitor hiV Practice

HIV Positive

Australia
407 Doctors
Bristol-Myers Squibb; Merck Sharp & Dohme LLC

Unknown

Once Daily 3TC, Efavirenz and ddI for HIV Infection

HIV Infection | AIDS

Australia
University of Modena and Reggio Emilia

Completed

Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles (Aging_in_HIV)

HIV Infection | Aging

Australia, Italy, Spain
Center for Eye Research Australia

Completed

Pilot Study of a Suprachoroidal Retinal Prosthesis

Retinitis Pigmentosa | Choroideremia

Australia
Bayside Health

Terminated

Associations, Outcomes and Genomics of GB Virus C, Hepatitis C Virus and Human Immunodeficiency Virus Infection

HIV Infections | Hepatitis C

Australia
The University of Queensland

Not yet recruiting

Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside (ATNAD)

Ataxia Telangiectasia

Australia
The University of Queensland
National Health and Medical Research Council, Australia

Completed

Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With a Novel Form of Anaplerosis (A-TC7)

Ataxia Telangiectasia

Australia
Kirby Institute
Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme LLC; Gilead Sciences; Hoffmann-La... and other collaborators

Terminated

Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy

HIV Infections | HIV-Associated Lipodystrophy

Australia
Institut National de la Santé Et de la Recherche...

Recruiting

X-linked Moesin Associated Immunodeficiency (X-MAIDReg)

Infections | Autoimmune Diseases | Diagnosis | Immune Deficiency

France, United States, Australia, Belgium, Japan, Netherlands
Kirby Institute
The Alfred; Peter MacCallum Cancer Centre, Australia; St Vincent's Hospital; Monash... and other collaborators

Active, not recruiting

Age-related Clonal Haematopoiesis in an HIV Evaluation Cohort (ARCHIVE) (ARCHIVE)

HIV Infections | Aging

Australia
Oslo University Hospital
St John of God Hospital, Vienna; Nepean Blue Mountains Local Health District

Completed

Bowel ENDOmetriosis; Evaluation of Diagnostics and Quality of Life (ENDO)

Quality of Life | Pain, Chronic | Deep Endometriosis | Bowel Dysfunction | Endometriosis Related Pain | Endometriosis Rectum | Deep Infiltrating Endometriosis

Norway, Australia, Austria
Hoffmann-La Roche

Withdrawn

ESP Study: A Study to Assess the Effect of Adding Fuzeon (Enfuvirtide) to an Antiretroviral Regimen in Fuzeon-Naive Patients With Sustained HIV Viral Suppression.

HIV Infections

Australia
CSL Limited

Completed

Ig NextGen 10% in Idiopathic Thrombocytopenic Purpura (ITP) Patients

Idiopathic Thrombocytopenic Purpura (ITP)

Australia
University of California, San Francisco
National Institute of Allergy and Infectious Diseases (NIAID); Monash University and other collaborators

Completed

Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study

HIV | Human Immunodeficiency Virus

United States, Australia
Kirby Institute
Merck Sharp & Dohme LLC

Completed

The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection (PINT)

HIV Infection

Australia
Murdoch Childrens Research Institute
Royal Children's Hospital

Completed

What is the Incidence of an Immune Disorder in Children With Invasive Pneumococcal Disease (IPD)?

Primary Immunodeficiency | Invasive Pneumococcal Disease, Protection Against | Invasive Pneumococcal Disease, Recurrent Isolated, 1 | Invasive Pneumococcal Disease, Recurrent Isolated, 2

Australia, New Zealand
Kirby Institute
National Heart, Lung, and Blood Institute (NHLBI); St Vincent's Hospital, Sydney

Completed

HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)

Cardiovascular Disease | HIV-Associated Lipodystrophy Syndrome

Australia
Clinuvel Pharmaceuticals Limited

Completed

Phase III Trial of CUV1647 in Polymorphic Light Eruption (PLE)

Polymorphic Light Eruption (PLE)

Austria, Australia, United Kingdom
Azora Therapeutics Australia Pty Ltd

Completed

Study of Efficacy and Safety of Investigational Treatment in Patients With Hidradenitis Suppurativa

Hidradenitis Suppurativa

Australia

Clinical Trials on Immunologic Disease in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations